Finance

Lists
CCCC:NASDAQ
C4 Therapeutics, Inc
$2.76
-0.36%
(-0.0100) 1D
$2.76
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CCCC...
Open
$2.76
High
$2.85
Low
$2.67
Mkt. cap
362.44M
Avg. vol.
2.91M
Volume
2.54M
52-wk high
$5.17
52-wk low
$1.69
EPS
-$0.72
Beta
3.17
Shares outstanding
131.32M
No. of employees
104
Open
$2.76
High
$2.85
Low
$2.67
Mkt. cap
362.44M
Avg. vol.
2.91M
Volume
2.54M
52-wk high
$5.17
52-wk low
$1.69
EPS
-$0.72
Beta
3.17
Shares outstanding
131.32M
No. of employees
104
News stories
From web sources and news partners
About C4 Therapeutics, Inc
CEO-
Employees104
Founded2015
HeadquartersWatertown, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to CCCC in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CCCC in the last 3 months.
Highest
Current $2.76
$11.00 (+298.55%)
Average
$8.50 (+207.97%)
Lowest
$6.00 (+117.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Bradley Canino
Guggenheim
Buy
Reiterated
$6.00
+117.4%
11/05/2026
Etzer Darout
Barclays
Buy
Maintained
$7.00
+153.6%
11/06/2026
Chad Messer
Lake Street
Buy
Initiated
$11.00
+298.6%
10/28/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$7.00
+153.6%
10/21/2026
Anupam Rama
J.P. Morgan
Buy
Initiated
$10.00
+262.3%
10/09/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$10.00
+262.3%
08/12/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/11/2026
Akash Tewari
Jefferies
Buy
Maintained
$14.00
+407.2%
04/30/2026
Unknown Analyst
Jefferies
Buy
Maintained
$14.00
+407.2%
04/10/2026
Leah R. Cann
Brookline Capital Markets
Buy
Maintained
$30.00
+987%
02/23/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.16 / -$0.21
+22.58%beat
Revenue / Est. (USD)
8.47M / 8.52M
-0.58%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
11.02M
6.15M
6.64M
8.47M
Cost of goods sold
-70.28M
24.61M
24.47M
24.80M
Cost of revenue
-70.28M
24.61M
24.47M
24.80M
Research and development expenses
95.26M
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.18M
9.33M
8.59M
8.26M
Operating expense
104.44M
9.33M
8.59M
8.26M
Total operating expenses
34.16M
33.94M
33.06M
33.06M
Operating income
-23.14M
-27.78M
-26.42M
-24.60M
Other non operating income
-
-
-
-
EBT including unusual items
-20.36M
-25.13M
-23.64M
-21.84M
EBT excluding unusual items
-21.23M
-26.22M
-23.64M
-21.84M
Income tax expense
121.00K
-
-
-
Effective tax rate
-0.59%
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.49M
-25.13M
-23.64M
-21.84M
Net profit margin
-185.97%
-408.47%
-355.90%
-257.95%
Earnings per share
-0.18
-0.20
-0.18
-0.16
Interest and investment income
1.92M
1.57M
2.79M
2.75M
Interest expense
-
-
-
-
Net interest expenses
1.92M
1.57M
2.79M
2.75M
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.72M
-27.38M
-26.13M
-24.28M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps